Back

Eliminating hepatitis C

Prior to the introduction of Direct Acting Antivirals (DAAs) therapy, hepatitis C affected more than 250,000 Australians resulting in up to 630 deaths from liver cancer and liver failure each year.

Due to the result of the introduction of DAA treatments and the associated high cure rates, the number of people estimated to be still living with hepatitis C at the end of 2023 – 68,890.

In Australia, of the estimated 74, 400 people living with hepatitis C, 20% of people do not know they have the virus. An estimated 60,240 people have been diagnosed with hepatitis C but have not been cured. Treatment is more than 95% effective at curing hepatitis C. Despite Australia’s progress, data from this year’s report show that declines in testing and treatment have been substantial over recent years; without a reinvigoration of efforts to prevent new infections, and an increase in the number of people diagnosed and treated, Australia will not achieve its elimination goals.

There are many benefits of testing and treating people for hepatitis C:

  • Hepatitis C is curable
  • Stops further transmission of hepatitis C
  • Prevent liver cirrhosis and liver cancer
  • Improve the quality of the person’s physical, mental and social wellbeing
  • Provide optimal evidenced-based healthcare for people who may have experienced trauma, disadvantage, marginalisation, substance use and stigma.

The goal of elimination

The World Health Organization has set a target to eliminate viral hepatitis as a public health threat by 2030. Elimination is defined as a 90% reduction in new chronic infections and a 65% reduction in mortality, compared with the 2015 baseline. To do this, we need to increase the testing and treatment of people who have hepatitis C. By participating in this program, you will be helping us work towards this goal.

References

  1. Burnet Institute and Kirby Institute: Burnet Institute | Kirby Institute
  2. Australia’s progress towards hepatitis C elimination: annual report 2024.
  3.  Melbourne: Burnet Institute; 2024.